{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:47:36Z","timestamp":1787240856108,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":1418,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009401","name":"Medizinischen Fakult\u00e4t, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","award":["F\u00f6FoLe No. 002"],"award-info":[{"award-number":["F\u00f6FoLe No. 002"]}],"id":[{"id":"10.13039\/501100009401","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1186\/s13613-022-01017-5","type":"journal-article","created":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T23:44:22Z","timestamp":1653263062000},"page":"44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Does the cytokine adsorber CytoSorb\u00ae reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study"],"prefix":"10.1016","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03985605","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christina","family":"Scharf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Weinelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Paal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zoller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Irlbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Briegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-0923","authenticated-orcid":false,"given":"Uwe","family":"Liebchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1186\/s13613-022-01017-5_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i1585","article-title":"Sepsis pathophysiology and clinical management","author":"Gotts","year":"2016","journal-title":"British Med J"},{"key":"10.1186\/s13613-022-01017-5_bb0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1186\/s13613-022-01017-5_bb0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(18)30696-2","article-title":"Sepsis and septic shock","volume":"392","author":"Cecconi","year":"2018","journal-title":"Lancet"},{"key":"10.1186\/s13613-022-01017-5_bb0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13613-019-0530-y","article-title":"Cytokine removal in human septic shock: where are we and where are we going?","volume":"9","author":"Honore","year":"2019","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-022-01017-5_bb0030","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-022-01017-5_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/CCM.0000000000000330","article-title":"Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program","volume":"42","author":"Ferrer","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-022-01017-5_bb0040","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-022-01017-5_bb0045","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the clinical use of vancomycin","volume":"60","author":"\u00c1lvarez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-022-01017-5_bb0050","unstructured":"German S2k guideline parenteral antibiotics 2020 https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/S82-006l_S2k_Parenterale_Antibiotika_2018-1.pdf."},{"key":"10.1186\/s13613-022-01017-5_bb0055","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1186\/s13613-022-01017-5_bb0060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s00134-018-5464-6","article-title":"Hemoadsorption with CytoSorb\u00ae","volume":"45","author":"Poli","year":"2019","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-022-01017-5_bb0065","unstructured":"CytoSorbents Europe GmbH https:\/\/cytosorb-therapy.com."},{"key":"10.1186\/s13613-022-01017-5_bb0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.aca.2014.10.009","article-title":"Bioanalytical chemistry of cytokines\u2014a review","volume":"853","author":"Stenken","year":"2015","journal-title":"Anal Chim Acta"},{"key":"10.1186\/s13613-022-01017-5_bb0075","article-title":"Cytosorb\u00ae hemoadsorption of apixaban during emergent cardio pulmonary bypass: a case report","author":"Mendes","year":"2020","journal-title":"Perfusion"},{"key":"10.1186\/s13613-022-01017-5_bb0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40635-020-00313-3","article-title":"Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study","volume":"8","author":"Lang","year":"2020","journal-title":"Intensive Care Med Exp"},{"key":"10.1186\/s13613-022-01017-5_bb0085","first-page":"358","article-title":"Venlafaxine intoxication with development of takotsubo cardiomyopathy: successful use of extracorporeal life support, intravenous lipid emulsion and cytosorb\u00ae. Int J Artif Organs","volume":"40","author":"Schroeder","year":"2017","journal-title":"SAGE Pub Ltd STM"},{"key":"10.1186\/s13613-022-01017-5_bb0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0391398818812601","article-title":"In vitro removal of anti-infective agents by a novel cytokine adsorbent system","volume":"42","author":"K\u00f6nig","year":"2019","journal-title":"Int J Artif Org"},{"key":"10.1186\/s13613-022-01017-5_bb0095","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000063108","article-title":"In vitro removal of therapeutic drugs with a novel adsorbent system","volume":"20","author":"Reiter","year":"2002","journal-title":"Blood Purif"},{"key":"10.1186\/s13613-022-01017-5_bb0100","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0391398820917151","article-title":"Elimination of glycopeptide antibiotics by cytokine hemoadsorption in patients with septic shock: a study of three cases","volume":"43","author":"Dimski","year":"2020","journal-title":"Int J Artif Organs"},{"key":"10.1186\/s13613-022-01017-5_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/aor.13952","article-title":"Impact of CytoSorb on kinetics of vancomycin and bivalirudin in critically ill patients","author":"Scandroglio","year":"2021","journal-title":"Artif Organs"},{"key":"10.1186\/s13613-022-01017-5_bb0110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000500013","article-title":"What have we learned about the use of cytosorb adsorption columns?","volume":"48","author":"Ankawi","year":"2019","journal-title":"Blood Purif"},{"key":"10.1186\/s13613-022-01017-5_bb0115","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jcrc.2020.08.027","article-title":"The ONTAI study\u2014a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units","volume":"60","author":"Liebchen","year":"2020","journal-title":"J Crit Care"},{"key":"10.1186\/s13613-022-01017-5_bb0120","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-022-01017-5_bb0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Programs in Biomed"},{"key":"10.1186\/s13613-022-01017-5_bb0130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1186\/s13613-022-01017-5_bb0135","doi-asserted-by":"crossref","first-page":"10493","DOI":"10.1038\/s41598-021-89965-z","article-title":"Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption","volume":"11","author":"Schneider","year":"2021","journal-title":"Sci Rep"},{"key":"10.1186\/s13613-022-01017-5_bb0140","unstructured":"European Medicines Agency 2018 Investigation of drug interactions. https:\/\/www.ema.europa.eu\/en\/investigation-drug-interactions."},{"key":"10.1186\/s13613-022-01017-5_bb0145","doi-asserted-by":"crossref","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction failure in intensive care units: results of a multicentre, prospective study Working group on \u201csepsis-related problems\u201d of the European society of intensive care medicine","author":"Vincent","year":"1998","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-022-01017-5_bb0150","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1097\/CCM.0000000000000317","article-title":"The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*","volume":"42","author":"Jamal","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-022-01017-5_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/s40560-018-0330-8","article-title":"Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy a monte carlo simulation study","author":"Chaijamorn","year":"2018","journal-title":"J Intensive Care"},{"key":"10.1186\/s13613-022-01017-5_bb0160","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11095-020-02832-w","article-title":"An integrated dialysis pharmacometric (idp) model to evaluate the pharmacokinetics in patients undergoing renal replacement therapy","volume":"37","author":"Broeker","year":"2020","journal-title":"Pharm Res"},{"key":"10.1186\/s13613-022-01017-5_bb0165","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1093\/jac\/dkt261","article-title":"A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy","volume":"68","author":"Beumier","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-022-01017-5_bb0170","first-page":"196","article-title":"Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis","volume":"63","author":"van de Vijsel","year":"2010","journal-title":"Can J Hosp Pharm"},{"key":"10.1186\/s13613-022-01017-5_bb0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00228-019-02755-5","article-title":"Pharmacokinetics of and maintenance dose recommendations for vancomycin in severe pneumonia patients undergoing continuous venovenous hemofiltration with the combination of predilution and postdilution","volume":"76","author":"Li","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1186\/s13613-022-01017-5_bb0180","article-title":"Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy","author":"Li","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1186\/s13613-022-01017-5_bb0185","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1186\/s13613-022-01017-5_bb0190","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10096-012-1803-7","article-title":"A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals","volume":"32","author":"Buyle","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1186\/s13613-022-01017-5_bb0195","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1093\/jac\/dkv165","article-title":"The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs","volume":"70","author":"Tabah","year":"2015","journal-title":"J Antimicrob Chemother"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-022-01017-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-022-01017-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025006144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025006144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-022-01017-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:39:11Z","timestamp":1776670751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025006144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2110582025006144"],"URL":"https:\/\/doi.org\/10.1186\/s13613-022-01017-5","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does the cytokine adsorber CytoSorb\u00ae reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-022-01017-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Author(s) 2022. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"44"}}